Circassia Pharmaceuticals
 | |
| Public limited company | |
| Traded as | LSE: CIR |
| Industry | Pharmaceuticals |
| Founded | 2006 |
| Headquarters | Oxford, United Kingdom |
Key people |
Francesco Granata, (Chairman) Steven Harris, (CEO) |
| Revenue | £10.8 million (2015)[1] |
| £(66.4) million (2015)[1] | |
| £(50.0) million (2015)[1] | |
| Website | www.circassia.co.uk |
Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange.
History
The company was founded by Steve Harris and Charles Swingland in 2006.[2] It was the subject of an Initial Public Offering in March 2014.[3]
Operations
The company's technology, ToleroMune, was initially developed by scientists at Imperial College London.[2] The company is in the process of developing a treatment for cat allergies.[4]
References
- 1 2 3 "Accounts for year ended 31 December 2015". Circassia Pharmaceuticals. Retrieved 31 March 2016.
- 1 2 "Fundamentals for Circassia Pharmaceuticals Ord 0.08p". The Telegraph. Retrieved 23 August 2014.
- ↑ "Circassia IPO Fuels Optimism on European Biotech". Wall street Journal. 13 March 2014. Retrieved 23 August 2014.
- ↑ "Hope of cat allergy cure brings Circassia to stock market". The Telegraph. 6 February 2014. Retrieved 23 August 2014.
External links
This article is issued from Wikipedia - version of the 9/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.